Total Payments
$684.31
2024 Payments
$30.54
Companies
22
Transactions
42
Medicare Patients
1,008
Medicare Billing
$68,515
Payment Breakdown by Category
Food & Beverage$668.08 (97.6%)
Education$16.23 (2.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $668.08 | 41 | 97.6% |
| Education | $16.23 | 1 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $113.90 | 6 | $0 (2019) |
| GENZYME CORPORATION | $66.24 | 3 | $0 (2019) |
| Genentech USA, Inc. | $59.54 | 4 | $0 (2019) |
| Celgene Corporation | $53.72 | 3 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $50.49 | 3 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $40.25 | 3 | $0 (2024) |
| Lilly USA, LLC | $38.24 | 3 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $30.13 | 2 | $0 (2019) |
| Daiichi Sankyo Inc. | $28.45 | 2 | $0 (2017) |
| TESARO, Inc. | $25.47 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30.54 | 2 | Ipsen Biopharmaceuticals, Inc ($16.23) |
| 2023 | $12.84 | 1 | E.R. Squibb & Sons, L.L.C. ($12.84) |
| 2020 | $20.21 | 1 | GlaxoSmithKline, LLC. ($20.21) |
| 2019 | $186.03 | 10 | GENZYME CORPORATION ($66.24) |
| 2018 | $165.26 | 11 | Celgene Corporation ($36.10) |
| 2017 | $269.43 | 17 | Amgen Inc. ($53.08) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/22/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: Oncology | ||||||
| 04/24/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 07/18/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.84 | General |
| Category: Oncology | ||||||
| 01/17/2020 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2019 | Lilly USA, LLC | ALIMTA (Drug), CYRAMZA, VERZENIO | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: Oncology | ||||||
| 10/14/2019 | GENZYME CORPORATION | LIBTAYO (Drug) | Food and Beverage | In-kind items and services | $21.02 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2019 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $11.17 | General |
| Category: Oncology | ||||||
| 10/10/2019 | GENZYME CORPORATION | LIBTAYO (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2019 | Genentech USA, Inc. | Perjeta (Biological), Kadcyla, TECENTRIQ | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: BioOncology | ||||||
| 08/23/2019 | Amgen Inc. | KANJINTI (Biological), Nplate, Prolia | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Oncology | ||||||
| 08/20/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.72 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2019 | GENZYME CORPORATION | LIBTAYO (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: ONCOLOGY | ||||||
| 03/21/2019 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $25.47 | General |
| Category: ONCOLOGY | ||||||
| 03/20/2019 | Amgen Inc. | Kyprolis (Biological), XGEVA | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: Oncology | ||||||
| 06/05/2018 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $11.98 | General |
| 05/17/2018 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO | Food and Beverage | In-kind items and services | $12.06 | General |
| Category: Oncology | ||||||
| 05/15/2018 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $11.14 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2018 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: Oncology | ||||||
| 05/07/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $12.41 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2018 | Bayer HealthCare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $11.32 | General |
| Category: Oncology | ||||||
| 03/15/2018 | Amgen Inc. | Neulasta (Biological), XGEVA | Food and Beverage | In-kind items and services | $26.06 | General |
| Category: Oncology | ||||||
| 03/15/2018 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $19.90 | General |
| 03/12/2018 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $16.61 | General |
| 02/22/2018 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $10.60 | General |
| Category: Oncology | ||||||
| 02/19/2018 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 213 | 312 | $57,161 | $13,144 |
| 2022 | 5 | 252 | 331 | $58,532 | $15,980 |
| 2021 | 2 | 123 | 130 | $25,319 | $4,398 |
| 2020 | 12 | 420 | 5,434 | $108,596 | $34,993 |
Total Patients
1,008
Total Services
6,207
Medicare Billing
$68,515
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 179 | 275 | $50,875 | $11,739 | 23.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 21 | 21 | $4,830 | $1,190 | 24.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 13 | 16 | $1,456 | $215.36 | 14.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 167 | 241 | $44,585 | $11,787 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 20 | 21 | $4,872 | $1,599 | 32.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 24 | 24 | $5,520 | $1,417 | 25.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 28 | 30 | $2,730 | $784.12 | 28.7% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 13 | 15 | $825.00 | $393.03 | 47.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 99 | 103 | $19,055 | $3,405 | 17.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 24 | 27 | $6,264 | $993.28 | 15.9% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2020 | 16 | 4,760 | $23,800 | $14,108 | 59.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 161 | 213 | $39,405 | $8,557 | 21.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 38 | 61 | $14,152 | $3,868 | 27.3% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 26 | 26 | $10,790 | $2,667 | 24.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 16 | 16 | $2,784 | $1,250 | 44.9% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 20 | 20 | $4,600 | $1,214 | 26.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 22 | 22 | $2,696 | $1,133 | 42.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 12 | 12 | $2,532 | $621.57 | 24.5% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 24 | 26 | $2,366 | $537.16 | 22.7% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2020 | 11 | 16 | $1,488 | $365.62 | 24.6% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 15 | 27 | $1,755 | $329.61 | 18.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 30 | 30 | $2,010 | $312.81 | 15.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2020 | 16 | 192 | $192.00 | $20.50 | 10.7% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2020 | 13 | 13 | $26.00 | $8.91 | 34.3% |
About Dr. John Barton, M.D
Dr. John Barton, M.D is a Medical Oncology healthcare provider based in Murfreesboro, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467407429.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Barton, M.D has received a total of $684.31 in payments from pharmaceutical and medical device companies, with $30.54 received in 2024. These payments were reported across 42 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($668.08).
As a Medicare-enrolled provider, Barton has provided services to 1,008 Medicare beneficiaries, totaling 6,207 services with total Medicare billing of $68,515. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Murfreesboro, TN
- Active Since 05/24/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1467407429
Products in Payments
- Neulasta (Biological) $79.14
- LIBTAYO (Drug) $66.24
- ZEJULA (Drug) $45.68
- Finacea (Drug) $39.17
- Abraxane (Drug) $37.11
- KEYTRUDA (Biological) $30.13
- TECENTRIQ (Biological) $29.96
- Perjeta (Biological) $29.58
- INJECTAFER (Drug) $28.45
- TASIGNA (Drug) $25.94
- SUBSYS (Drug) $18.81
- Kyprolis (Biological) $17.98
- KANJINTI (Biological) $16.78
- Onivyde (Drug) $16.23
- FASLODEX (Drug) $15.63
- ALIMTA (Drug) $15.01
- BOSULIF (Drug) $14.85
- KISQALI (Drug) $14.31
- BENDEKA (Drug) $13.97
- OPDIVO (Biological) $12.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.